Nitin Rohatgi

No bio available.

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Astra Zeneca
    Date added:
    09/28/2024
    Date updated:
    09/28/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Pfizer
    Date added:
    09/28/2024
    Date updated:
    09/28/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Natera
    Date added:
    09/28/2024
    Date updated:
    09/28/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Astellas
    Date added:
    09/28/2024
    Date updated:
    09/28/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Lilly
    Date added:
    09/28/2024
    Date updated:
    09/28/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Novartis
    Date added:
    09/28/2024
    Date updated:
    09/28/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Gilead
    Date added:
    09/28/2024
    Date updated:
    09/28/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    BMS
    Date added:
    09/28/2024
    Date updated:
    09/28/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Stemline
    Date added:
    09/28/2024
    Date updated:
    09/28/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Merck
    Date added:
    09/28/2024
    Date updated:
    09/28/2024

Pages

Return to Northern California Hematology Oncology Conference: A Tumor Board Case-Based Approach to the Latest Breakthroughs